Last reviewed · How we verify
Phase 1: Conventiaonal DMARD
Phase 1: Conventiaonal DMARD is a Small molecule drug developed by Pfizer. It is currently FDA-approved.
Pfizer's conventional DMARD is currently marketed, positioning it as an established treatment in the rheumatoid arthritis segment. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the loss of exclusivity post-2028, which could significantly impact revenue.
At a glance
| Generic name | Phase 1: Conventiaonal DMARD |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phase 1: Conventiaonal DMARD CI brief — competitive landscape report
- Phase 1: Conventiaonal DMARD updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Phase 1: Conventiaonal DMARD
What is Phase 1: Conventiaonal DMARD?
Who makes Phase 1: Conventiaonal DMARD?
What development phase is Phase 1: Conventiaonal DMARD in?
Related
- Manufacturer: Pfizer — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing